Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer
|
|
- Colin Earl Richards
- 5 years ago
- Views:
Transcription
1 1119 Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer Genes&Cancer 1(11) TheAuthor(s)2011 Reprintsandpermission: sagepub.com/journalspermissions.nav DOI: / asabumi Shibuya Abstract Ligands and their tyrosine kinase (TK) receptors regulate a variety of biological systems in animals. Vascular endothelial growth factor (VEGF) and its receptor (Flt/VEGFR family) system play a crucial role not only in physiological but also in most parts of pathological angiogenesis including cancer. Flt-1/VEGFR-1 and KDR/VEGFR-2 bind VEGF-A but have different functions on angiogenesis at early embryogenesis: Flt-1 has a negative role by trapping ligands, whereas KDR (Flk1 in mice) exerts a strong positive signal, resulting in a balance in blood vessel formation. At adult stages, however, both VEGFRs contribute to pathological angiogenesis either directly or through stimulation of migration/activation of macrophage lineage cells and stimulate tumor growth, metastasis, and inflammation. VEGFRs activate downstream signaling of the phospholipase Cγ protein kinase C AP kinase pathway but not Ras pathway for cell proliferation. The VEGF-C/D and Flt-4/VEGFR-3 system regulates lymphangiogenesis. Thus, VEGFs as well as these receptor TKs are attractive targets for suppressing pathological angiogenesis. Keywords: vascular endothelial growth factor, tyrosine kinase receptor, phospholipase C, tumor angiogenesis Introduction Receptor-type as well as nonreceptortype TKs are major signal transducers in various systems in vertebrates including angiogenesis. Historically, researches on TKs had started in In 1980, a viral Src protein, designated v-src, was identified as the first tyrosine kinase in animals. After that, nonreceptor TKs such as v-fps and v-yes as well as receptor-type TKs such as v-erbb (epidermal growth factor receptor [EGFR]) were isolated as viral oncogenes. At this time, no structurally mutated or activated TK gene had yet been found in human tumors. We found that glioblastomas often carry a mutated form of the EGFR gene: about one-third of the ligandbinding domain was deleted at the genomic DNA level, and this mutant EGFR (now known as EGFRvIII) was constitutively active without the ligand EGF. 2 Several groups including our own demonstrated that the Shc-Grb2/Sos-Ras pathway is essential for the downstream signaling of EGFR towards cell proliferation and transformation. During these studies, we learned how the Ras pathway plays a major role in intracellular signaling in typical TKs with oncogenic potential. The question is whether any nonreceptor-type TK/receptor-type TK is not associated with oncogenic potential nor with the Ras pathway but promotes biological systems such as tumor angiogenesis. As described later, the VEGFR family appears to be an example. Isolation of flt-1 cdna and Its Unique Expression Pattern In 1987, we obtained a genomic DNA that carries an exon-like structure possibly encoding a portion of receptor-type TK (TKR). 3 Since TKR is thought to be pro-oncogenic, a higher gene expression and mutations of this new gene are expected in human tumors. However, most of the tumor cells examined so far did not express it at detectable levels. We thought it might be a pseudogene, but finally, its expression was detected in placenta, and a full-length cdna of about 8 kb was isolated for this new TK. 4 A few years later, several groups including our own found that this gene is specifically expressed in vascular endothelial cells. 5-8 Unique Structure of the New TKR, Flt-1 The amino acid sequence encoded in the cdna was unique: it carried 7 immunoglobulin (Ig) domains in the extracellular domain, a transmembrane domain, Department of olecular Oncology, Tokyo edical and Dental University, Tokyo, Japan, and Jobu University, Isesaki, Japan Corresponding Author: asabumi Shibuya, Department of olecular Oncology, Tokyo edical and Dental University, Yushima, Bunkyo-ku, Tokyo , Japan shibuya@ims.u-tokyo.ac.jp
2 1120 Genes & Cancer / vol1no11(2010) Figure 1. The VEGF-VEGFR system in mammals. VEGF-A and 3 VEGFR genes are essential for normal angiogenesis during embryogenesis. Knockout mice of these genes are embryonic lethal due to abnormality of blood vessel formation. In the case of the VEGF-A gene, even the heterozygote mice die in embryogenesis because of the dysfunction of blood vessels. and a TK domain with a kinase insert (KI) about 70 amino acids long (Fig. 1). The entire structure indicates that it is a new type of TKR, distantly related to the family of Fms, Kit, and PDGFR, which contain 5 Ig domains in the extracellular domain, known as the PDGFR family/ 5-Ig-TKR family. Since, at that time, the Fms tyrosine kinase oncogene was the most famous of the 5-Ig-TKRs, we designated this new gene flt-1 (fms-like tyrosine kinase-1) in ,9-11 Another interesting feature of Flt-1 is that, although the 5-Ig-TKRs have a tyrosine (Y)-x-x-methionine () motif in the KI region critical for PI3 kinase/ Akt activation and for a strong mitotic signal, the Flt-1 KI region did not have this motif. 4 A second member of the Flt-1 family/7-ig-tkr family, KDR (Flk-1 in mice), isolated in 1991, did not have this motif either, strongly suggesting that the intracellular signaling pathway of the Flt family/7-ig-tkr family is quite different from that of the 5-Ig-TKRs. 12,13 In 1992, de Vries et al. showed that vascular endothelial growth factor (VEGF) binds Flt-1 with high affinity and activates its kinase activity. 5 It is well known that pathological angiogenesis is crucial to the development of various diseases including cancer. 14 The VEGF-VEGFR (Flt family) system could play a central role in tumor angiogenesis. Therefore, several groups decided to focus on the molecular biology of angiogenesis, particularly on VEGF-VEGFRs. 15 A few years later, Alitalo s group isolated a third member of the Flt family, Flt-4 (VEGFR-3), and a new ligand, VEGF-C, which specifically binds VEGFR-3. The VEGF-C/D and VEGFR3 system mostly regulates lymphangiogenesis. 16 Characteristics of the Signaling of VEGFRs The novel structure of VEGFRs, lacking the PI3K activation motif (Y-x-x-) in the KI region, suggests a unique signaling system in vascular endothelial cells. 6 We found that, unlike typical TKRs such as EGFR, neither VEGFR-1 nor VEGFR-2 showed any cell-transforming activity toward NIH3T3 fibroblasts. These observations further support that the intracellular signaling from VEGFR-1/VEGFR-2 is different from that for typical TKs. VEGFR-2 has TK activity about one order of magnitude stronger than that of VEGFR-1, and the gene knockout of VEGFR-2/flk-1 in mice indicated that it is the major positive signal transducer in angiogenesis. 17,18 We found that the signaling of VEGFR-2 is unique among TKs, with almost no activation of Ras but strong activation of a phospholipase Cγ (PLCγ) PKC pathway towards activation of AP kinase and proliferation of vascular endothelial cells in response to VEGF. 19 Furthermore, we identified that a single amino acid residue, Y-1175, in human VEGFR-2 (Y at 1173 in mice) is a major autophosphorylation site for the stimulation of the PLCγ-PKC pathway in vitro. 20 To show that this pathway is really used in animals, we made a knockin mouse with a single amino acid mutation at 1173 from Y to phenylalanine (F). Homozygotes with the 1173F/1173F mutation demonstrated severe angiogenic defects, resulting in embryonic death at E9.0, although VEGFR-2 was expressed and TK activity was maintained. 21 These results indicate that the VEGFR2-Y1175-PLCγ-PKC pathway is crucial for vasculogenesis and angiogenesis in vivo. Lawson et al. also supported the importance of this pathway in angiogenesis in zebrafish. 22 Involvement of VEGFR-1 in Carcinogenesis VEGFR-1 (Flt-1) has very high affinity for VEGF (Kd = ) but about 10-fold less kinase activity than VEGFR-2. Fong et al. showed that flt-1 / mice die in the embryonic stage due to the overgrowth and disorganization of blood vessels. 23 This indicates that Flt-1 has a negative role in proangiogenic signaling early in embryogenesis and achieves an appropriate balance in terms of this signaling. We examined whether a high-affinity ligand-binding
3 TyrosinekinaseFlt/VEGFRsregulateangiogenesisandcancer/Shibuya 1121 molecules (sorafenib and sunitinib) were developed and have been widely used in clinics for the treatment of colorectal, breast, lung (nonepithelial), hepatic, and renal cancers as well as glioblastomas. Figure 2. Premetastatic activation in the lung via VEGFR-1 (Flt-1) signaling. Transplanted tumors in mice induce macrophage lineage cell migration and P9 expression in the lung before metastasis. VEGFR-1 signal deficient mice (flt-1 TK / mice) show less migration of macrophages and P9 expression as well as decreased metastasis, indicating these processes to be partly dependent on VEGFR-1 TK signaling. Involvement of Flt-1/VEGFR-1 in Other Diseases Flt-1 is expressed not only in vascular endothelial cells but also in macrophage lineage cells and regulates VEGForiented migration, survival, and angiogenic factor production. Using the wild-type and Flt-1 TK / mice, inflammatory responses such as immune cell infiltration, angiogenesis, and edema in the knee joints were found to be significantly weaker in TK / mice than in wild-type mice in a rheumatoid arthritis (RA) model. 32 Taken together, these results suggest that the TK signaling of Flt-1 is a potential target for treatment of cancer and RA. Soluble Flt-1 and Pre-eclampsia domain or a weak TK is important for this negative role of Flt-1 by making Flt-1 TK domain deficient mice. The Flt-1 TK / mice lacked the TK domain but had the ligand-binding domain and T domain. Surprisingly, they were basically healthy, and their angiogenesis was almost normal. This indicates the major role of Flt-1 in early embryogenesis to be the trapping of the VEGF molecule with a Flt-1 ligand-binding domain. 24 Since Flt-1 TK / mice are missing the signaling from Flt-1 kinase, they are useful for analyzing the involvement of Flt-1 signaling in various diseases. By using normal mice and Flt-1 TK / mice, Flt-1 kinase was shown to be important for promotion of the lung-oriented metastasis of 3LL-LLC (a highly metastatic variant of Lewis lung carcinoma) via premetastatic induction of matrix metalloproteinase 9 (P9) in the lung 25 (Fig. 2). In a similar experimental model, Kaplan et al. demonstrated that VEGFR1- positive hematopoietic bone marrow progenitors initiate the premetastatic niche in the lung and other tissues, stimulating tissue-oriented tumor metastasis. 26 We have recently found that the signaling of Flt-1 kinase stimulates melanoma and uterine tumor growth at the primary site in mice via recruitment of bone marrow derived monocyte/macrophages into tumor tissues. 27,28 Furthermore, Tammela et al. reported that Flt-4/VEGFR-3 promotes not only lymphangiogenesis but also tumor angiogenesis. 29 On the other hand, the contribution of a ligand of Flt-1, placenta growth factor (PlGF), to tumor growth appears context dependent; thus, whether the PlGF-neutralizing antibody has a strong tumor-suppressive effect in vivo is not clarified yet. 30,31 Based on these researches, not only VEGFR-2 but also VEGFR-1 as well as VEGFR-3 were shown to be an attractive target for suppression of tumor angiogenesis. VEGF-A neutralizing monoclonal antibody (bevacizumab) and multikinase inhibitors of small In 1990, 2 major transcripts of flt-1 were described: one for the full-length TKR, and another for a short protein without the TK region. 4 Later, the structure of soluble Flt-1 was characterized and was found to contain only the ligand-binding domain. We found that soluble Flt-1 is conserved not only in mammals but also in birds. In the placenta in mammals, soluble Flt-1 was reported to be expressed in trophoblasts, which form a border between the maternal and fetal blood vessels. Since soluble Flt-1 has very high affinity for VEGF, it is likely a natural inhibitor of the VEGF system, negatively regulating excess angiogenesis or hyperpermeability in the placenta. Recent studies strongly suggest that an abnormally high level of soluble Flt-1 in the placenta causes maternal pathological symptoms in pre-eclampsia such as hypertension and renal dysfunction It is of interest that an anti-vegf-a neutralizing antibody, bevacizumab (Avastin, Genentech Inc., South San Francisco, CA), now widely used in clinics for the treatment of
4 1122 Genes & Cancer / vol1no11(2010) various solid tumors, has side effects such as hypertension and proteinuria. Thus, excess trapping of VEGF-A in the body by the soluble Flt-1 produced during pre-eclampsia appears to be the major cause of the maternal symptoms of this disease, suggesting suppression of the function of soluble Flt-1 to be a good strategy for treatment. Other VEGF-Like olecules In addition to the studies on angiogenesis described above, VEGF-E encoded in a parapoxvirus genome was found to activate only VEGFR-2, stimulating less inflammatory and well-organized blood vessels. 36 On the other hand, another VEGF-like protein (T.f.svVEGF) specifically expressed in the venom of the habu snake increases vascular permeability, most likely for the rapid distribution of toxins in prey. 37 These results further support that VEGF-VEGFR is a crucial system for regulating angiogenesis and vascular permeability and is widely used not only in animals but also in viruses. Conclusion The benefits of the anti-vegf and anti- VEGFR medicines for cancer patients are clear; however, they are still limited. In the Delta-Notch system, a neutralizing antibody against Dll4 (Delta-like 4) was shown to be effective for suppression of tumor growth in mice. 38,39 However, more recently, Yan et al. reported that anti-dll4 antibody treatment often induced a tumor, angioma, in mice, suggesting a risk in the host animals. 40 We found that double-deprivation stress with hypoxia and low nutrition, which mimics a condition under antiangiogenic therapy, induces a resistant phenotype in tumor cells. 41 Thus, further studies are necessary to elucidate the mechanism of tumor resistance against antiangiogenic therapy and to find a new strategy to overcome this resistance. Acknowledgments Starting in Saburo s laboratory, I have had a wonderful period of research on TKs lasting more than 30 years. I dedicate this review to the memory of Saburo and Teruko Hanafusa. I also thank all the alumni and staff of Hanafusa s laboratory and colleagues in Japan as well as all over the world. Declaration of Conflicting Interests The author declared no potential conflicts of interest with respect to the authorship and/or publication of this article. Funding This work was supported by Grant-in-aid Special Project Research on Cancer-Bioscience from the inistry of Education, Culture, Sports, Science and Technology of Japan. References 1. Jove R, Hanafusa H. Cell transformation by the viral src oncogene. Annu Rev Cell Biol. 1987;3: Yamazaki H, Fukui Y, Ueyama Y, et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbb) in human brain tumors. ol Cell Biol. 1988;8: atsushime H, Yoshida C, Sasaki, Shibuya. A possible new member of tyrosine kinase family, human frt sequence is highly conserved in vertebrates and located on human chromosome 13. Jpn J Cancer Res (Gann). 1987;78: Shibuya, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5: De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255: Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269: Yamane A, Seetharam L, Yamaguchi S, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene. 1994;9: Kaipainen A, Korhonen J, Pajusola K, et al. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp ed. 1993;178: Shibuya. Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67: Shibuya, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312: Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438: Terman BI, Carrion E, Kovacs E, et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene. 1991; 6: atthews W, Jordan CT, Gavin, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cdna isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci U S A. 1991;88: Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86: Shibuya. Vascular permeability/vascular endothelial growth factor. In: Figg W, Folkman J, editors. Angiogenesis: an integrative approach from science to medicine. New York: Springer; p Alitalo K, Carmeliet P. olecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1: Sawano A, Takahashi T, Yamaguchi S, Aonuma T, Shibuya. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor (PlGF), which is related to vascular endothelial growth factor (VEGF). Cell Growth Diff. 1996;7: Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376: Takahashi T, Ueno H, Shibuya. VEGF activates protein kinase C-dependent, but Rasindependent Raf-EK-AP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18: Takahashi T, Yamaguchi S, Chida K, Shibuya. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EBO J. 2001;20: Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya. Essential role of Flk-1 (vascular endothelial growth factor receptor-2) tyrosine residue-1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A. 2005;102: Lawson ND, ugford JW, Diamond BA, Weinstein B. Phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development. Genes Dev. 2003;7: Fong GH, Rossant J, Gertsentein, Breitman L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376: Hiratsuka S, inowa O, Kuno J, Noda T, Shibuya. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998;95: Hiratsuka S, Nakamura K, Iwai S, et al. P9 induction by vascular endothelial growth factor receptor-1 is involved in lung specific metastasis. Cancer Cell. 2002;2: Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438: Kerber, Reiss Y, Wickersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008;68: uramatsu, Yamamoto S, Osawa T, Shibuya. VEGF-1 signaling promotes mobilization of macrophage-lineage cells from bone marrow and stimulateolid tumor growth. Cancer Res. In press.
5 TyrosinekinaseFlt/VEGFRsregulateangiogenesisandcancer/Shibuya Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454: Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell. 2010;141: Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010;141: urakami, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/macrophages. Blood. 2006;108: aynard SE, in JY, erchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111: Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (svegfr-1) levels in women with preeclampsia. J Clin Endocrinol etab. 2003;88: Levine RJ, aynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J ed. 2004;350: Kiba A, Sagara H, Hara T, Shibuya. VEGFR- 2-specific ligand VEGF-E induces nonedematous hyper-vascularization in mice. Biochem Biophys Res Commun. 2003;301: Takahashi H, Hattori S, Iwamatsu A, Takizawa H, Shibuya. A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J Biol Chem. 2004;279: Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444: Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444: Yan, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463:E Osawa T, uramatsu, Watanabe, Shibuya. Hypoxia and low nutrition double stress induces aggressiveness in a murine model of melanoma. Cancer Sci. 2009;100:
Review of relationship between vascular endothelial growth factor family & receptors and tumor angiogenesis
16 1 2004 2 hinese Bulletin of Life Sciences Vol. 16, No. 1 Feb., 2004 1004-0374 (2004) 01-0019-05 1 201203 2 200025 (vascular endothelial growth factor, ) (vascular permeability factor, VPF), -A -B -
More informationThe Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis
The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis Nam Deuk Kim, Ph.D. Pusan National University Contents Part 1. The process of angiogenesis Part 2. The role of angiopoietins
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationStructure and Function of VEGF/VEGF-receptor System Involved in Angiogenesis
CELL STRUCTURE AND FUNCTION 26: 25 35 (2001) 2001 by Japan Society for Cell Biology REVIEW Structure and Function of VEGF/VEGF-receptor System Involved in Angiogenesis Masabumi Shibuya Institute of Medical
More informationSignaling Vascular Morphogenesis and Maintenance
Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan Science 277: 48-50, in Perspectives (1997) Blood vessels are constructed by two processes: vasculogenesis, whereby a primitive vascular
More informationGenetics and Cancer Ch 20
Genetics and Cancer Ch 20 Cancer is genetic Hereditary cancers Predisposition genes Ex. some forms of colon cancer Sporadic cancers ~90% of cancers Descendants of cancerous cells all cancerous (clonal)
More informationTHE HALLMARKS OF CANCER
THE HALLMARKS OF CANCER ONCOGENES - Most of the oncogenes were first identified in retroviruses: EGFR (ErbB), Src, Ras, Myc, PI3K and others (slightly more than 30) - Mutated cellular genes incorporated
More informationCYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
More informationThe Angiopoietin Axis in Cancer
Ang2 Ang1 The Angiopoietin Axis in Cancer Tie2 An Overview: The Angiopoietin Axis Plays an Essential Role in the Regulation of Tumor Angiogenesis Growth of a tumor beyond a limiting size is dependent upon
More informationMechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
More informationAngiogenesis as a therapeutic target
Angiogenesis as a therapeutic target Lecture Experimentelle Krebsforschung SS 07 Prof. Gerhard Christofori Institute of Biochemistry and Genetics Department of Clinical-Biological Sciences University of
More informationInflammatory Cells and Metastasis
Inflammatory Cells and Metastasis Experimentelle Krebsforschung SS 07 Gerhard Christofori Institute of Biochemistry and Genetics Department of Clinical-Biological Sciences Center of Biomedicine University
More informationMembrane Fixation of Vascular Endothelial Growth Factor Receptor 1 Ligand-Binding Domain Is Important for Vasculogenesis and Angiogenesis in Mice
MOLECULAR AND CELLULAR BIOLOGY, Jan. 2005, p. 346 354 Vol. 25, No. 1 0270-7306/05/$08.00 0 doi:10.1128/mcb.25.1.346 354.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Membrane
More informationGenome of Hepatitis B Virus. VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department
Genome of Hepatitis B Virus VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department Proto Oncogen and Oncogen Oncogen Proteins that possess the ability to cause
More informationDeregulation of signal transduction and cell cycle in Cancer
Deregulation of signal transduction and cell cycle in Cancer Tuangporn Suthiphongchai, Ph.D. Department of Biochemistry Faculty of Science, Mahidol University Email: tuangporn.sut@mahidol.ac.th Room Pr324
More informationCell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger
Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)
More informationReceptor mediated Signal Transduction
Receptor mediated Signal Transduction G-protein-linked receptors adenylyl cyclase camp PKA Organization of receptor protein-tyrosine kinases From G.M. Cooper, The Cell. A molecular approach, 2004, third
More informationBackgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?
Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits
More informationOMONDI OGUDE MEDICAL ONCOLOGY
OMONDI OGUDE MEDICAL ONCOLOGY Personalized medicine (Targeted therapy) In recent years there s been a move from conventional cytotoxic therapy to more targeted therapy Mostly due to the rapid pace of
More informationAngiogenesis, blood vessel formation, is essential. VEGFR and Type-V RTK Activation and Signaling. Masabumi Shibuya 1,2
VEGFR and Type-V RTK Activation and Signaling Masabumi Shibuya 1,2 1 Jobu University, Isesaki, Gunma 372-8588, Japan 2 Department of Molecular Oncology, Tokyo Medical and Dental University, Bunkyo-ku,
More informationEGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling
EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads
More informationMolecular Oncology, oncology parameters see each test
Molecular Oncology, oncology parameters see each test DPD deficiency Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is an autosomal recessive metabolic disorder in which there is absent or
More informationTissue repair. (3&4 of 4)
Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid
More informationBiologics Effects of Targeted Therapeutics
Report on the isbtc Mini-symposium on Biologics Effects of Targeted Therapeutics Michael B. Atkins, MD Beth Israel Deaconess Medical Center Louis Weiner, M.D. Fox Chase Cancer Center Report on the isbtc
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationEts-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs Indian Patent Application No. 1623/DEL/2014 Inventors: Prof. Kulbhushan Tikoo and Jasmine Kaur Department of Pharmacology
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More information1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?
1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal
More informationThe Role of Targeted Therapy in Metastatic Colorectal Cancer Patient Care
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/conversations-colorectal-cancer/the-role-of-targeted-therapy-inmetastatic-colorectal-cancer-patient-care/10272/
More informationESC Congress August 2011 Paris France. VEGFs and the angiogenic paradox in diabetic patients
ESC Congress 2011 27. 31. August 2011 Paris France VEGFs and the angiogenic paradox in diabetic patients Session: New features and effects of angiogenic growth factors in vascular diseases. Johannes Waltenberger,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationTargeting angiogenesis in cancer
New Indigo workshop on Antiparasitic and Antitumour drugs IBMC, 9 th September, 2011 Targeting angiogenesis in cancer Raquel Soares Department of Biochemistry Tumor angiogenesis: therapeutic implications
More informationRAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.
۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,
More informationDetermination Differentiation. determinated precursor specialized cell
Biology of Cancer -Developmental Biology: Determination and Differentiation -Cell Cycle Regulation -Tumor genes: Proto-Oncogenes, Tumor supressor genes -Tumor-Progression -Example for Tumor-Progression:
More informationProcessing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis
Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis ii Colloquium Digital Library of Life Sciences This e-book is an original work
More informationAngiogenic and cell survival functions of vascular endothelial growth factor (VEGF).
Royal College of Surgeons in Ireland e-publications@rcsi Surgery Articles Department of Surgery 1-10-2005 Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). Anne Marie
More informationReview of Hallmarks of Prostate Cancer (PCa) Nilgoon Zarei* Keywords: Prostate Cancer (PCa), Hallmarks of Cancer
Article Health Professional Student Journal 2015 2(1) Review of Hallmarks of Prostate Cancer (PCa) Nilgoon Zarei* Abstract: Prostate cancer (PCa) is the most frequently diagnosed noncutaneous malignancy
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationTransformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture:
Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture: Spandana Baruah December, 2016 Cancer is defined as: «A disease caused
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationWHY TARGETTING SIGNALLING PATHWAYS?
WHY TARGETTING SIGNALLING PATHWAYS? Cancer cells are particularly sensitive to stress therefore sensitive to inhibition of their hyper activated signaling proteins the re instatement of lost tumor suppressors.
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More informationConcise Reference. HER2 Testing in Breast Cancer. Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli
Concise Reference Testing in Breast Cancer Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli Extracted from Handbook of -Targeted Agents in Breast Cancer ublished by Springer
More information1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications
Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationTyrosine kinases. Cell surface receptors ligand binding. Producer cell RNA. Target cell
Tyrosine kinases http://msbl.helsinki.fi/tkseminar roducer cell Signaling molecules Receptor binding Signal transduction Target cell Activation of Gene expression RNA Biological responses proliferation,
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationResearch Article Vascular Endothelial Growth Factor Receptor-1 Expression in Breast Cancer and Its Correlation to Vascular Endothelial Growth Factor A
International Breast Cancer Volume 2013, Article ID 746749, 6 pages http://dx.doi.org/10.1155/2013/746749 Research Article Vascular Endothelial Growth Factor Receptor-1 Expression in Breast Cancer and
More informationAngiogenesis in Human Development. Vascular Development
Angiogenesis in Human Development Jan Kitajewski ICRC 217B, ph 851-4688, email: jkk9 BACKGROUND READING: Vascular Development Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan. Science 277:
More informationEarly Embryonic Development
Early Embryonic Development Maternal effect gene products set the stage by controlling the expression of the first embryonic genes. 1. Transcription factors 2. Receptors 3. Regulatory proteins Maternal
More informationANALYSIS OF THE VEGFR1 (FLT-1) ISOFORMS IN VASCULAR DEVELOPMENT. Nicholas Chris Kappas
ANALYSIS OF THE VEGFR1 (FLT-1) ISOFORMS IN VASCULAR DEVELOPMENT Nicholas Chris Kappas A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of
More informationColorectal Cancer Treatment Future Directions
Colorectal Cancer Treatment Future irections Margot F. Sweed CRNP Fox Chase Cancer Center M_Sweed Sweed@FCCC. @FCCC.edu April 2005 What s the Target? Agents in clinical trials PTK 787/ZK SUO11248 Panitumumab
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationAngiostasis and Angiogenesis Regulated by Angiopoietin1-Tie2 Receptor System
Japan-Mexico Workshop on Pharmacology and Nanobiology Feb. 25, 2009; Universidad Nacional Autönoma de Mëxico, Mexico City Angiostasis and Angiogenesis Regulated by Angiopoietin1-Tie2 Receptor System Shigetomo
More information!!! Oncology for Scientists (RPN 530) Metastasis and Angiogenesis Chapter 13 and 14 Oct. 28 th 2014
Oncology for Scientists (RPN 530) Metastasis and Angiogenesis Chapter 13 and 14 Oct. 28 th 2014 Department of Cancer Genetics Masashi Muramatsu, Ph.D. About Exam First, think and understand the concepts.
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationCell Signaling part 2
15 Cell Signaling part 2 Functions of Cell Surface Receptors Other cell surface receptors are directly linked to intracellular enzymes. The largest family of these is the receptor protein tyrosine kinases,
More informationoncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
More informationDrug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
More informationHow genetic & biochemical alterations in brain tumors contribute to epileptogenesis
How genetic & biochemical alterations in brain tumors contribute to epileptogenesis December 2 nd, 2012 Joon H. Uhm, MD FRCPC Departments of Neurology & Oncology Mayo Clinic, Rochester, MN American Epilepsy
More informationPredicting benefit from antiangiogenic
Predicting benefit from antiangiogenic agents in malignancy Adrian M. Jubb*, Adam J. Oates, Scott Holden and Hartmut Koeppen Abstract A high probability of benefit is desirable to justify the choice of
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationBiochemical and Biophysical Research Communications
Biochemical and Biophysical Research Communications 375 (2008) 287 291 Contents lists available at ScienceDirect Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
More informationCOMPARATIVE VEGF RECEPTOR TYROSINE KINASE MODELING FOR THE DEVELOPMENT OF HIGHLY SPECIFIC INHIBITORS OF TUMOR ANGIOGENESIS
243 COMPARATIVE VEGF RECEPTOR TYROSINE KINASE MODELING FOR THE DEVELOPMENT OF HIGHLY SPECIFIC INHIBITORS OF TUMOR ANGIOGENESIS ULRIKE SCHMIDT 1 JESSICA AHMED 1 ulrike.schmidt@charite.de jessica.ahmed@charite.de
More informationCancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationChapter 11 CYTOKINES
Chapter 11 CYTOKINES group of low molecular weight regulatory proteins secreted by leukocytes as well as a variety of other cells in the body (8~30kD) regulate the intensity and duration of the immune
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationSALSA MLPA probemix P315-B1 EGFR
SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional
More informationVascular endothelial growth factor (VEGF) signaling in tumor progression. Robert Roskoski, Jr. Blue Ridge Institute for Medical Research
Vascular endothelial growth factor (VEGF) signaling in tumor progression Robert Roskoski, Jr. Blue Ridge Institute for Medical Research 3754 Brevard Road, Suite 116A, Box 19 Horse Shoe, NC 28742 USA E-mail
More informationEnzyme-coupled Receptors. Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors
Enzyme-coupled Receptors Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors Cell-surface receptors allow a flow of ions across the plasma
More informationOrigin of oncogenes? Oncogenes and Proto-oncogenes. Jekyll and Hyde. Oncogene hypothesis. Retroviral oncogenes and cell proto-oncogenes
Oncogenes and Proto-oncogenes Jekyll and Hyde A double edged sword Origin of oncogenes? Oncogene hypothesis Retroviral oncogenes and cell proto-oncogenes (v-onc) (c-onc) The role of c-onc in cancer How
More informationProblem Set 8 Key 1 of 8
7.06 2003 Problem Set 8 Key 1 of 8 7.06 2003 Problem Set 8 Key 1. As a bright MD/PhD, you are interested in questions about the control of cell number in the body. Recently, you've seen three patients
More informationPhospholipase C γ Prof. Graham Carpenter
Graham Carpenter, h.d. rofessor of Biochemistry Cornelia Crooke Department of Biochemistry Vanderbilt University School of Medicine, Nashville, TN 1 Receptor Tyrosine Kinases GF Extracellular M Intracellular
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationOncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber
Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber jweber@dom.wustl.edu Oncogenes & Cancer DNA Tumor Viruses Simian Virus 40 p300 prb p53 Large T Antigen Human Adenovirus p300 E1A
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationGenetics of Cancer Lecture 32 Cancer II. Prof. Bevin Engelward, MIT Biological Engineering Department
Genetics of Cancer Lecture 32 Cancer II rof. Bevin Engelward, MIT Biological Engineering Department Why Cancer Matters New Cancer Cases in 1997 Cancer Deaths in 1997 Genetics of Cancer: Today: What types
More informationDevelopment of Next-generation Therapeutic
2015 World Biologics Korea Development of Next-generation Therapeutic Antibodies for Treating Ovarian Cancer (Therapeutic Targeting of Tetraspanin8 in Epithelial Ovarian Cancer Invasion and Metastasis)
More informationSignaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research
Signaling Dr. Sujata Persad 3-020 Katz Group Centre for Pharmacy & Health research E-mail:sujata.persad@ualberta.ca 1 Growth Factor Receptors and Other Signaling Pathways What we will cover today: How
More informationMechanism and Therapeutic Potential of Statin-Mediated Inhibition of Tyrosine Kinase Receptors. Tong Tong Zhao
Mechanism and Therapeutic Potential of Statin-Mediated Inhibition of Tyrosine Kinase Receptors Tong Tong Zhao Thesis submitted to the Faculty of Graduate and Postdoctoral Studies In partial fulfillment
More informationOncolytic Virotherapy: Targeting Cancer Stem Cells
Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:
More informationChapter 4 Cellular Oncogenes ~ 4.6 -
Chapter 4 Cellular Oncogenes - 4.2 ~ 4.6 - Many retroviruses carrying oncogenes have been found in chickens and mice However, attempts undertaken during the 1970s to isolate viruses from most types of
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More informationGENE THERAPY IN CARDIOVASCULAR DISEASES ASAN MEDICAL CENTER KI HOON HAN MD
GENE THERAPY IN CARDIOVASCULAR DISEASES ASAN MEDICAL CENTER KI HOON HAN MD GENE THERAPY 1. CORRECT GENES 2. CURE WITH GENES WHAT IS GENE? DNA ( deoxyribonucleic acid ) - DOUBLE HELICAL STRUCTURE GENE ;
More informationHeterotypy and Angiogenesis
Heterotypy and Angiogenesis Tumors are perpetual wounds 1. Normally stroma and epithelia converse at a distance. 2. Juxtaposition of stroma and epithelia is indicative of tissue damage. 4. Activate strategies
More informationMetastasis progression
Metastasis progression Mieloma multiplo Linear Progression Cancer cells disseminate through the organism after acquiring metastatic features inside the primary cancer Parallel progression Cancer cells
More informationOncogenes and tumour suppressor genes
Cancer mutations disrupt cellular homeostasis Oncogenes and tumour suppressor genes Oncogenes: Gain of function mutations Proto-oncogene Tumour suppressor genes: loss of function mutations Normal cell
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationKEY CONCEPT QUESTIONS IN SIGNAL TRANSDUCTION
Signal Transduction - Part 2 Key Concepts - Receptor tyrosine kinases control cell metabolism and proliferation Growth factor signaling through Ras Mutated cell signaling genes in cancer cells are called
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More information